Literature DB >> 23027411

Cognitive impairment in schizophrenia.

Richard S E Keefe1, Philip D Harvey.   

Abstract

Cognitive functioning is moderately to severely impaired in patients with schizophrenia. This impairment is the prime driver of the significant disabilities in occupational, social, and economic functioning in patients with schizophrenia and an important treatment target. The profile of deficits in schizophrenia includes many of the most important aspects of human cognition: attention, memory, reasoning, and processing speed. While various efforts are under way to identify specific aspects of neurocognition that may lie closest to the neurobiological etiology and pathophysiology of the illness, and may provide relevant convergence with animal models of cognition, standard neuropsychological measures continue to demonstrate the greatest sensitivity to functionally relevant cognitive impairment.The effects of antipsychotic medications on cognition in schizophrenia and first-episode psychosis appear to be minimal. Important work on the effects of add-on pharmacologic treatments is ongoing. Very few of the studies completed to date have had sufficient statistical power to generate firm conclusions; recent studies examining novel add-on treatments have produced some encouraging findings. Cognitive remediation programs have generated considerable interest as these methods are far less costly than pharmacologic treatment and are likely to be safer. A growing consensus suggests that these interventions produce modest gains for patients with schizophrenia, but the efficacy of the various methods used has not been empirically investigated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027411     DOI: 10.1007/978-3-642-25758-2_2

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  98 in total

1.  Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Robert R Bies; Takayuki Abe; Ariel Graff-Guerrero; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2013-07-01       Impact factor: 9.306

Review 2.  Dynamic network communication as a unifying neural basis for cognition, development, aging, and disease.

Authors:  Bradley Voytek; Robert T Knight
Journal:  Biol Psychiatry       Date:  2015-04-28       Impact factor: 13.382

Review 3.  Using model systems to understand errant plasticity mechanisms in psychiatric disorders.

Authors:  Bruno B Averbeck; Matthew V Chafee
Journal:  Nat Neurosci       Date:  2016-10-26       Impact factor: 24.884

Review 4.  Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.

Authors:  Jason Smucny; Jason R Tregellas
Journal:  J Psychopharmacol       Date:  2017-04-26       Impact factor: 4.153

5.  Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme.

Authors:  Laigao Chen; Nabeel Nabulsi; Mika Naganawa; Kenneth Zasadny; Marc B Skaddan; Lei Zhang; Soheila Najafzadeh; Shu-Fei Lin; Christopher J Helal; Tracey L Boyden; Cheng Chang; Jim Ropchan; Richard E Carson; Anabella Villalobos; Yiyun Huang
Journal:  J Nucl Med       Date:  2016-05-19       Impact factor: 10.057

6.  Transmembrane protein 108 is required for glutamatergic transmission in dentate gyrus.

Authors:  Hui-Feng Jiao; Xiang-Dong Sun; Ryan Bates; Lei Xiong; Lei Zhang; Fang Liu; Lei Li; Hong-Sheng Zhang; Shun-Qi Wang; Ming-Tao Xiong; Mihir Patel; Alexis M Stranahan; Wen-Cheng Xiong; Bao-Ming Li; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 7.  Cognitive remediation in schizophrenia-The view from India.

Authors:  Smita N Deshpande; Triptish Bhatia; E Mohandas; Vishwajit L Nimgaonkar
Journal:  Asian J Psychiatr       Date:  2016-06-24

8.  Altered prefrontal activity and connectivity predict different cognitive deficits in schizophrenia.

Authors:  Fabio Ferrarelli; Brady A Riedner; Michael J Peterson; Giulio Tononi
Journal:  Hum Brain Mapp       Date:  2015-08-19       Impact factor: 5.038

9.  Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia.

Authors:  Daniel W Chung; Kenneth N Fish; David A Lewis
Journal:  Am J Psychiatry       Date:  2016-07-22       Impact factor: 18.112

10.  Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults.

Authors:  Hsun-Hua Chou; Jo A Talledo; Sarah N Lamb; Wesley K Thompson; Neal R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2013-01-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.